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Editorial
‘Small’ randomised neo-adjuvant
chemotherapy trials in breast cancer
reporting on pathological response: more
harm than good?
The main clinical advantage of neo-adjuvant chemotherapy in
operable breast cancer is that it has improved the ability to
perform breast-conserving therapy. In addition, it can be con-
sidered as an ideal model for studying chemosensitivity in
vivo [1]. Observations from early studies, both single arm
phase II studies and those randomising pre-operative systemic
therapy against post-operative adjuvant therapy, have con-
firmed that those women whose tumours have a pathological
complete response to neo-adjuvant chemotherapy have the
best long-term outcome, and this remains true after multivari-
ate analysis [2, 3]. Therefore, pathological complete response
is now considered as a surrogate for survival and since the
mid-1990s, clinicians have made this a primary or secondary
end point in randomised trials of pre-operative chemotherapy.
It has even been suggested that regimens achieving a higher
proportion of patients in pathological complete response
should then be used in the adjuvant setting as they must give
a survival improvement on older treatments. The TOPIC 2
trial, which is published in this issue of Annals of Oncology,
is one of these randomised trials, looking to improve upon a
conventional adjuvant regimen [4]. We felt that it would be
interesting, therefore, to put this trial into perspective with
other small randomised neo-adjuvant chemotherapy trials that
have also reported pathological complete response results
(Table 1) [5–16].
The TOPIC 2 trial randomised 451 patients with large oper-
able breast cancer to receive either six cycles of doxorubicin
and cyclophosphamide (AC) in the standard arm or six cycles
of vinorelbine and epirubicin (VE) in the experimental arm, to
be followed by locoregional treatment. The authors report in
this issue the first results on response and tolerability, and the
bottom line is that there is no difference in clinical response or
pathological response between the two arms, although the toxi-
city profiles are slightly different (more alopecia and nausea
with AC and more thrombophlebitis and neuropathy with VE).
The primary end point of the TOPIC 2 trial was to detect an
improvement in the 5-year relapse-free survival from 50% in
the standard arm to 65% in the experimental arm. This assump-
tion is, in the light of current adjuvant chemotherapy results,
extremely optimistic. A more realistic design would have been
to make the pathological complete response rate the primary
end point (in this trial it was a secondary end point). In this
report there is no difference in the pathological response rates
between the two treatment arms, which therefore makes it very
unlikely that a clinically relevant or statistically significant dis-
ease-free survival difference will emerge when the final analy-
sis is performed after the planned 190 events.
Has this or any of the other ‘small’ randomised neo-adju-
vant chemotherapy trials influenced clinical practice? The
short answer should be ‘no, they cannot’, since most of these
trials have yet to report on survival. However, in reality they
have wrongly changed practice in many centres despite the
fact that these data are not sufficient to be considered level 1
evidence. The best example is what happened as a conse-
quence of the ‘Aberdeen’ trial, where some practices were
changed as a consequence of data from 97 patients random-
ised to either continue with anthracycline chemotherapy or
switch to a taxane [5]. Those patients switched to the taxane
had a higher pathological complete response, which appeared
to translate to a survival advantage [6]. Any change in practice
is clearly not the fault of the Aberdeen breast group, whose
design was novel, looking to further improve the outcome for
those women whose tumours were sensitive to the first che-
motherapy; but a trial with only 97 randomised patients, and
no independent review of the pathological response, should
have been seen by the oncology community as only sufficient
for hypothesis generating. Similar comments apply for any
other change of practice based on any of the trials in Table 1,
which report differences in pathological complete response
between two chemotherapy arms or regimens.
The main issue is the uncertain biological significance of a
pathological complete response. Is it a pure prognostic factor
for a good outcome with systemic chemotherapy, or a predic-
tive factor representing a biological parameter influenced by
the specific treatment and not just the intrinsic biology of the
tumour? If pathological complete response is a predictive fac-
tor, an increase of the pathological complete response rate in
a randomised trial comparing two chemotherapy regimens
should translate into a survival advantage. This is the hypothe-
sis behind much contemporary thinking in the breast oncology
community, but has it been demonstrated in a prospective
clinical trial? The answer is ‘not yet’, and the recent
results of National Surgical Adjuvant Breast and Bowel
Project Protocol B-27 suggest that it may not be true [17].
Early results of this trial have shown that the pathological
complete response rate was almost doubled in women treated
with neo-adjuvant doxorubicin AC followed by docetaxel
compared with AC alone (26.1% versus 13.7%) [18]. In
December 2004 the outcome data from this trial were pre-
sented at the San Antonio Breast Cancer Symposium with a
median follow-up of 69 months, and failed to demonstrate any
survival difference (relapse-free, distant disease-free or overall
survival) between the treatment arms [17]. A possible
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explanation for this lack of benefit is that both the treatment
duration and the number of chemotherapy cycles were differ-
ent. A longer duration of chemotherapy may have further
reduced the extent of local disease, such that some additional
pathological complete responses were identified, but without
an impact on the natural history of any micrometastatic dis-
ease. The ongoing EORTC 10 994/BIG 00-01 trial is rando-
mising over 1800 patients between two treatments with an
equal number of chemotherapy cycles over the same duration
(either six cycles of fluorouracil, epirubicin, and cyclophos-
phamide, or three cycles of docetaxel followed by three cycles
of epirubicin plus docetaxel), such that it will inform as to
whether a difference (if any) between the pathological com-
plete response rate with treatment A or B will translate into a
survival difference.
What can we conclude from these small randomised trials?
From a clinician’s perspective, it should be acknowledged that
these small trials that emphasised pathological complete
response rates, but cannot confirm their long-term benefit,
may have done more harm than good. This is because, based
on these data many clinicians have changed their practice and
have exposed their patients to additional, toxic chemotherapy.
From the standpoint of clinical research, one is tempted to say
that these trials did not meet our expectations. This would
imply that there is no more room for such small randomised
neo-adjuvant trials looking for pathological complete
responses, since any new regimens tested in the neo-adjuvant
setting must still be studied only in the context of large phase
III trials. However, I think exactly the opposite is true and
would like to argue for a structured future for ‘small’ random-
ised neo-adjuvant chemotherapy studies.
The first proposal would be to use pathological complete
response rate as a mandatory checkpoint, or early stopping
rule, when designing or developing a trial comparing two che-
motherapy regimens in early breast cancer. In such a design,
if there is no difference in pathological complete response rate
between the two (or more) treatment arms after inclusion of
a few hundred patients, well balanced between the arms for
factors predictive of pathological complete response, one
could reasonably hypothesise that no survival difference will
emerge even after inclusion of several thousands of patients.
For a trial aimed at equivalent efficacy but better toxicity we
could potentially stop the trial and switch to the better toler-
ated therapy; for one aimed to improve outcome, it would be
back to the drawing board to look for a newer strategy to be
tested. It would save money, as large trials are expensive,
Table 1. Pathological response rates in ‘small’ randomised trials comparing different regimens of neo-adjuvant chemotherapy
Study group [reference] n a Treatment A Treatment B pCR%b DFS%
Aberdeen [5, 6] 97 (162) CVAP 8 CVAP 4 ! D 4 16/34 (P= 0.04) 5-year DFS 78/93
(P= 0.04) (md fu 65 m)
ACCOG [7] 363 AC 6 q3w AD 6 q3w 24/21 (P= 0.61) No difference
(P= 0.17) (md fu 32 m)
AGO [8] 475 (631) EP 4 q3w E 3 ! P 3 q2w 10/18 (P= 0.03) NR
ETNA [9] 191 AP 4 AP 6 17/30 NR
French study [10] 200 AC 4 AP 4 10/16 No difference
(md fu 31 m)
6/8c
GEPARDO [11] 250 AD 4 q2w AD 4 q2w+ Tam 12/12 NR
GEPARDUO [12] 913d AD 4 q2w AC 4 ! D 4 q3w 7/14 (P<0.001) NR
GIREC [13] 90 FEC100 6 ED 6 24/24 NR
MDA [14] 174 CAF 4 P 4 16/8 (P=NS) 2-year DFS 89/94
(P= 0.44)
MDA [15] 258 P 4 q3w ! CAF 4 Weekly P 12 ! CAF 4 14/29 (P<0.01) NR
TOPIC [16] 426 AC 6 ECisF 6 25/24 NR
TOPIC 2 [4] 451 AC 6 VE 6 12/12 NR
an, number of patients randomised.
bDifferent pCR definitions were used.
cThe pCR% determined by study centre pathologists were 10 and 16 in the AC and AP treatment arms, respectively; these rates determined by an
independent expert review were 6 and 8, respectively.
dWith 913 patients, the inclusion of this study in the group of ‘small’ randomised trials is debatable. Of note, the enrolment in this study ended after an
interim analysis assessing the pCR% of the first 395 patients included in the trial (at that point 913 patients were already included). This analysis showed
a statistically significant higher pCR% for patients treated in arm B.
pCR, pathological complete response; DFS, disease-free survival; md fu, median follow-up; m, months; NR, not reported; CVAP, cyclophosphamide,
vincristine, doxorubicin, prednisolone; D, docetaxel; AC, doxorubicin, cyclophosphamide; AD, doxorubicin, docetaxel; EP, epirubicin, paclitaxel; P,
paclitaxel; AP, doxorubicin, paclitaxel; FEC100, fluorouracil, epirubicin, cyclophosphamide; ED, epirubicin, docetaxel; CAF, cyclophosphamide,
doxorubicin, fluorouracil; ECisF, epirubicin, cisplatin, infusional fluorouracil; VE, vinorelbine, epirubicin; Tam, tamoxifen; q3w, every 3 weeks; q2w,
every 2 weeks; NS, not significant.
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save patients toxicity, as new chemotherapy treatments are
usually more toxic, and save time, avoiding putting patients
into trials very unlikely to change practice. On the other hand,
if there is a difference in the rates of pathological complete
response, the trial should enter a second phase allowing the
inclusion of patients who could receive the chemotherapy
treatments being tested in the trial in either the neo-adjuvant
or the adjuvant setting. It is of interest to note that none of the
trials summarised in Table 1 used this strategy, including
those which demonstrated a pathological complete response
difference, despite obvious potential implications.
A second suggestion would be to explore new chemothe-
rapy regimens in the subgroup(s) of patients whose tumours
are more likely to respond to chemotherapy. Inclusion of
patients with little chance of obtaining a pathological com-
plete response could explain the negative or weakly positive
results of previously reported trials, since such patients would
dilute the overall rate of pathological complete response.
Several publications have shown higher pathological complete
response rates in tumours not expressing steroid hormone
receptors. In a retrospective study of 399 patients treated at
the European Institute of Oncology, the pathological response
rate of negative estrogen and progesterone receptor expression
compared with those having some expression was 33% and
7.5%, respectively [19]. Other studies reported similar results
[12, 18, 20]. Moreover, concentrating on a more homogeneous
group of tumours (such as those negative for both the estrogen
and progesterone receptor) could permit identification of fac-
tors predictive of response to a specific chemotherapy agent.
The third proposal, perhaps the most challenging, is the
integration of so called ‘targeted therapies’ in the neo-adjuvant
model. To illustrate this, we will concentrate on one group of
these targeted therapies, the anti-ErbB receptor family agents.
Taking the precedent of trastuzumab, these new molecules
could be used either as monotherapy, in combination with
different anti-receptor therapies or other molecular targeted
therapies (downstream signalling transduction inhibitors or
antiangiogenic molecules), or more simply in combination
with conventional chemotherapy. A recently published ran-
domised study gives a good example of the combined
approach with chemotherapy [21]. Patients with HER-2 posi-
tive large operable breast cancers were randomly assigned to
either four cycles of paclitaxel followed by four cycles of
fluorouracil, epirubicin and cyclophosphamide, or to the same
chemotherapy with concomitant weekly trastuzumab. The pri-
mary end point was the pathological complete response rate.
The trial was closed prematurely after inclusion of 42 patients
(out of 164 planned) because of a more than two-fold increase
in the pathological complete response rate favouring patients
who received the combined treatment (25% versus 66.7%;
P= 0.02). The main message from this trial is that the neo-
adjuvant model could rapidly test the synergy between che-
motherapy and a specific targeted therapy agent, trastuzumab,
and that this observation deserves further evaluation. How-
ever, this trial does not tell us that the standard neo-adjuvant
treatment of HER-2 tumours should be chemotherapy and
concomitant trastuzumab for at least two reasons. First, how-
ever encouraging the improvement in pathological complete
response rate, it remains a small trial, and any unintentional
imbalance between the two arms in factors (perhaps hitherto
unrecognised) that predict for sensitivity to the chemotherapy
could have given rise to a similar difference. Secondly, the
results of both the HERA trial and the US joint analysis pre-
sented at the ASCO meeting this year show very similar
reductions of the relative risk of relapse [22]. The difference
between the trials is that in the HERA trial, trastuzumab was
delivered after completion of adjuvant or neo-adjuvant chemo-
therapy, whereas the joint US trial analysis related to patients
given trastuzumab concomitantly with taxol chemotherapy.
Therefore, although the neo-adjuvant study appears to support
the addition of trastuzumab to the adjuvant treatment pro-
gramme, it cannot confirm when it should be given in terms
of either before surgery or concomitantly with the chemothe-
rapy. However, all is not rosy in the garden of combining
anti-ErbB agents and chemotherapy. Baselga and Arteaga [23]
recently emphasised in a review that the correlation between
preclinical models and clinical results is good with anti-HER-
2 therapies but very poor with anti-EGFR agents, as exempli-
fied by four negative phase III studies in non-small-cell lung
cancers. Had combinations of anti-EGFR therapies and con-
ventional agents been first tested in neo-adjuvant trials, with
the clinical and pathological tumour response analysed in vivo
along with biomarkers studies on repeated core biopsies (con-
comitantly with pharmacokinetic studies), then perhaps the
large phase III studies might not have been needed. Although
such studies may be more difficult to perform in lung cancer,
we would have no excuse not to perform these in breast
cancer.
Based on the three proposals mentioned above, an ‘ideal
study’ would commence with a phase I design followed by
a randomised phase II and only proceed to a phase III if there
was sufficient evidence to support such a large study. The
phase I would define the maximum tolerated dose and the
optimal biological dose. The aim of the subsequent random-
ised phase II should be to detect an increase in pathological
complete response rate with the novel therapy. If confirmed,
the study would extend into a phase III trial looking for a sur-
vival difference. If no significant difference in pathological
complete response rates are detected, this information would
avoid including several thousand patients in a phase III trial
unlikely to lead to a more effective therapy. At the same time,
tumour samples taken from both the phase II and phase III
studies could be used to identify whether there is a subgroup
of patients more likely to respond to the novel treatment. The
EORTC Breast Cancer Group is developing such an approach
looking to combine a novel anti-Her-2 therapy with a potent
single agent drug in breast cancer, docetaxel.
What have we learnt from small randomised trials such as
that reported by Chua et al. [4] in this issue? I think it is clear
that such studies on their own no longer have a place in the
development of better chemotherapy treatments in early breast
cancer. However, their basic design, together with parallel
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pathological response and marker assessments, has the poten-
tial to be a springboard to rapidly test novel combinations (i.e.
an anti-ErbB receptor family agent and conventional chemo-
therapy), which, when shown to be more effective, can be
tested for their true adjuvant benefit in a large definitive phase
III trial. The report by the TOPIC 2 trialists strongly suggests
that its research arm should not be taken forward to a large
phase III trial; but we, and our patients, are indebted to them
for preventing us running such a large trial that would have
been very unlikely to lead to a more effective therapy.
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